A concise BioPharma briefing for laboratory researchers. All compounds discussed are investigational and sold for research use only—not for human use.
BPC-157 Human Tissue Research
BPC-157 is trending after a 2026 study examined nitric-oxide-mediated vasorelaxation in isolated human internal mammary artery tissue. Compared with the compound’s larger animal and preclinical evidence base, human ex vivo tissue offers a more directly relevant mechanistic model. It is not a clinical trial, however, and cannot establish safety, efficacy, or therapeutic benefit in people.
Product Highlight: RAD-140
RAD-140 is a selective androgen receptor modulator used in controlled laboratory investigations of receptor selectivity and tissue-specific signaling. It is mechanistically distinct from BPC-157: RAD-140 targets androgen-receptor pathways, while BPC-157 research commonly examines peptide-mediated repair and vascular mechanisms. Neither compound is approved for human use.
Educational Tip: Rank Evidence Correctly
Do not treat “human tissue” as equivalent to “tested in humans.” Ex vivo studies isolate a mechanism under controlled conditions; clinical studies evaluate outcomes, exposure, adverse events, and variability in living participants. Record the model, comparator, concentration, sample source, and study limitations before comparing results across compounds.
Review RAD-140 Research Material
View the RAD-140 product page for laboratory specifications and research-use information.